Search Results for "1"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for 1. Results 1881 to 1890 of 2575 total matches.

Masoprocol for Multiple Actinic Keratoses

   
The Medical Letter on Drugs and Therapeutics • Oct 15, 1993  (Issue 907)
applied only the vehicle, the mean number of lesions decreased from 13.4 to 11.1. Among the patients who ...
Masoprocol cream 10% (meso-nordihydroguiaretic acid, Actinex - Reed and Carnrick) is now available in the USA for topical treatment of actinic keratoses.
Med Lett Drugs Ther. 1993 Oct 15;35(907):97-8 |  Show IntroductionHide Introduction

The Female Condom

   
The Medical Letter on Drugs and Therapeutics • Dec 24, 1993  (Issue 912)
— According to the manufacturer, each Reality condom will cost family planning clinics about $1 ...
A condom for women (Reality - Wisconsin Pharmacal) to prevent pregnancy and sexually transmitted diseases, including AIDS, has been approved for marketing by the US Food and Drug Administration (FDA). Already available in many family planning clinics, it will be available in pharmacies in a few months.
Med Lett Drugs Ther. 1993 Dec 24;35(912):123-4 |  Show IntroductionHide Introduction

Riluzole for Amyotrophic Lateral Sclerosis

   
The Medical Letter on Drugs and Therapeutics • Dec 08, 1995  (Issue 963)
. The premarketing supply is limited; the manufacturer (1-800-798-7425) has enough on hand to treat 3,000 ...
The US Food and Drug Administration (FDA) has approved 'early access' use of riluzole (Rilutek - Rh ne-Poulenc Rorer) for treatment of amyotrophic lateral sclerosis (ALS). is the first drug to become available for treatment of this condition. The premarketing supply is limited; the manufacturer (1-800-798-7425) has enough on hand to treat 3,000 of the 25,000 patients with the disease in the USA, and those 3,000 have already been selected through a lottery. Similar arrangements have been made in several European countries. Riluzole is not available commercially in any country.
Med Lett Drugs Ther. 1995 Dec 8;37(963):113-4 |  Show IntroductionHide Introduction

Topotecan Hydrochloride for Metastatic Ovarian Cancer

   
The Medical Letter on Drugs and Therapeutics • Oct 25, 1996  (Issue 986)
is 1.5 mg/m 2 given intravenously over 30 minutes daily for five consecutive days every 21 days ...
Topotecan hydrochloride (Hycamtin - SmithKline Beecham) was recently approved by the U.S. Food and Drug Administration for parenteral use as a single agent in patients with metastatic ovarian cancer refractory to other drugs. Initial treatment for metastatic ovarian cancer usually consists of cisplatin (Platinol) or carboplatin (Paraplatin) plus paclitaxel (Taxol) or cyclophosphamide (Cytoxan, and others).
Med Lett Drugs Ther. 1996 Oct 25;38(986):96-7 |  Show IntroductionHide Introduction

St. John's Wort

   
The Medical Letter on Drugs and Therapeutics • Nov 21, 1997  (Issue 1014)
in plasma is about 25 hours (B Staffeldt et al, J Geriatr Psychiatry Neurol, 7 suppl 1:S47, 1994 ...
Many readers have asked the Medical Letter to evaluate St. John's wort, an herbal extract now widely sold in health food stores and pharmacies, for its effectiveness and safety in the treatment of depression. St. John's wort is licensed in Germany for treatment of anxiety, depression and insomnia. In the USA, it is considered a dietary supplement and has not been evaluated by the FDA.
Med Lett Drugs Ther. 1997 Nov 21;39(1014):107-8 |  Show IntroductionHide Introduction

Valrubicin for Bladder Cancer

   
The Medical Letter on Drugs and Therapeutics • Mar 26, 1999  (Issue 1049)
). The cost of 800 mg (four 5-ml vials) is $1,560, according to wholesale price (AWP) listings in Drug Topics ...
Valrubicin (Valstar), formerly known as AD 32, has been approved by the FDA for intravesical treament of bladder cancer. The approval is limited to patients with carcinoma-in-situ refractory to BCG for whom immediate cystectomy is contraindicated.
Med Lett Drugs Ther. 1999 Mar 26;41(1049):32 |  Show IntroductionHide Introduction

Pneumococcal Vaccine

   
The Medical Letter on Drugs and Therapeutics • Sep 10, 1999  (Issue 1061)
(Advisory Committee on Immunization Practices, MMWR Morb Mortal Wkly Rep, 46 RR-8:1, 1997). Anatomic ...
Increased resistance of pneumococci to antimicrobial drugs may encourage more extensive use of pneumococcal polysaccharide vaccine.
Med Lett Drugs Ther. 1999 Sep 10;41(1061):84 |  Show IntroductionHide Introduction

A Transcutaneous Electrical Nerve Stimulation Device (Cefaly) for Migraine Prevention

   
The Medical Letter on Drugs and Therapeutics • Aug 18, 2014  (Issue 1449)
of 3 electrodes, each of which can be used up to 20 times, costs $25.1 CLINICAL STUDIES — Approval ...
The FDA has approved the use of a transcutaneous electrical nerve stimulation device (Cefaly – Cefaly Technology) for prevention of episodic migraine in patients ≥18 years old. The first device to be approved in the US for migraine prevention, it is available in Canada and Europe for treatment and prevention of migraines. A transcranial magnetic stimulation device (SpringTMS - eNeura Therapeutics) recently approved by the FDA for treatment of migraine preceded by aura will be reviewed in a future issue.
Med Lett Drugs Ther. 2014 Aug 18;56(1449):78 |  Show IntroductionHide Introduction

Turmeric Supplements

   
The Medical Letter on Drugs and Therapeutics • Nov 18, 2019  (Issue 1585)
varies. Premium Turmeric 1,000 mg capsules (TruNature) is the only USP-verifi ed turmeric product ...
Turmeric is a spice derived from the Curcuma longa plant. Dietary supplements and foods containing turmeric are widely promoted for relief of pain and to improve joint mobility, immunity, digestion, cardiovascular health, depression, anxiety, memory, and cognition.
Med Lett Drugs Ther. 2019 Nov 18;61(1585):185 |  Show IntroductionHide Introduction

Table: Some Drug Interactions with Drugs for IBD (online only)

   
The Medical Letter on Drugs and Therapeutics • Jul 10, 2023  (Issue 1680)
Sphingosine 1-phosphate (S1P) Receptor Modulator – Ozanimod flCoadministration of ozanimod and strong ...
View the Table: Some Drug Interactions with Drugs for IBD
Med Lett Drugs Ther. 2023 Jul 10;65(1680):e114   doi:10.58347/tml.2023.1680c |  Show IntroductionHide Introduction